



(51) International Patent Classification:

C07J 9/00 (2006.01) *A61P 1/16* (2006.01)
A61K 31/575 (2006.01) *C07J 51/00* (2006.01)

(21) International Application Number:

PCT/US2013/046150

(22) International Filing Date:

17 June 2013 (17.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/661,531 19 June 2012 (19.06.2012) US

(71) Applicant: INTERCEPT PHARMACEUTICALS, INC.
[US/US]; 18 Desbrosses Street, New York, NY 10013 (US).

(72) Inventors: STEINER, André; PharmaZell GmbH, Rosenheimer Str. 43, 83064 Raubling (DE). WAENERLUND POULSEN, Heidi; FeF Chemicals A/S, Kobenhavnsvej 216, DK-4600 Køge (DK). JOLIBOIS, Emilie; Pharmorphix Ltd., 250 Cambridge Science Park, Milton Road,

Cambridge CB4 0WE (GB). REWOLINSKI, Melissa; 4350 La Jolla Village Drive, Suite 960, San Diego, CA 92122 (US). GROSS, Ralf; PharmaZell GmbH, Rosenheimer Str. 43, 83064 Raubling (DE). SHARP, Emma; Pharmorphix Ltd., 250 Cambridge Science Park, Milton Road, Cambridge CB4 0WE (GB). DUBAS-FISHER, Fiona; Pharmorphix Ltd., 250 Cambridge Science Park, Milton Road, Cambridge CB4 0WE (GB). EBERLIN, Alex; Pharmorphix Ltd., 250 Cambridge Science Park, Milton Road, Cambridge CB4 0WE (GB).

(74) Agents: ELRIFI, Ivor, R. et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,

[Continued on next page]

(54) Title: PREPARATION, USES AND SOLID FORMS OF OBETICHOLIC ACID





FIG. 5



(57) **Abstract:** The present invention relates to obeticholic acid; or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.



SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*